Genprex Issues Stockholder Letter and Provides 2024 Corporate Update
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, announced significant achievements in its 2024 stockholder letter. The company has initiated two new lung cancer clinical trials and continues treating patients in an ongoing trial. By partnering with community-based oncology practices, Genprex aims to extend its clinical reach. They have also expanded preclinical research into new therapeutic areas, showcasing positive results at a major cancer conference. Additionally, their global intellectual property portfolio has been strengthened to protect their lead drug candidate. Genprex is optimistic about upcoming catalysts that will enhance its position in gene therapy.
- Initiation of two new lung cancer clinical trials.
- Ongoing patient treatment in a third lung cancer trial.
- Partnerships with community-based oncology practices to broaden clinical reach.
- Expansion into new therapeutic indications with positive preclinical data.
- Strengthened global intellectual property estate for lead drug candidate.
- None.
Genprex's progress in lung cancer clinical trials is a significant step forward for patients and investors. The initiation of two new trials and continued treatment in a third highlights the company's dedication to developing effective therapies. This could lead to more treatment options for lung cancer patients, potentially improving survival rates and quality of life. The fact that Genprex is partnering with community-based oncology practices is also notable. Such collaborations can accelerate patient enrollment and ensure a more diverse patient population, which is important for the robustness of clinical trial results.
However, it is essential to be cautiously optimistic. Clinical trials can be unpredictable and positive preclinical results do not always translate into successful clinical outcomes. Investors should keep an eye on the trial phases and any interim results released to better gauge the potential success of these therapies.
From a financial perspective, Genprex's progress in clinical development and expansion of its intellectual property (IP) estate are positive indicators. New clinical trials and a broader IP portfolio can attract investor confidence and potentially increase the company's market valuation. The CEO's mention of 'important catalysts' in the coming months suggests upcoming milestones that could be market-moving events. Such milestones could include interim trial results, partnerships, or regulatory updates, each of which has the potential to significantly impact the stock price.
However, investors should also consider the risks. Clinical-stage companies often face high operational costs and uncertain revenue streams. The ongoing trials and IP expansion require substantial financial resources and there is no guarantee of success. Therefore, it's important to monitor the company's financial health, including cash burn rate and funding activities. Ensuring that Genprex has sufficient capital to sustain its operations through these critical periods is essential.
Company Achieves Multiple Clinical Development Milestones in 2024
Patient Treatment Continues in Three Lung Cancer Clinical Trials
"Genprex continues to make progress across a number of areas critical to advancing our novel gene therapies in oncology and diabetes," said Ryan Confer, President and Chief Executive Officer. "So far this year, we have opened enrollment and have begun treating patients in two new lung cancer clinical trials, while we continued to treat patients in a third lung cancer clinical trial. We have partnered with a large network of community-based oncology practices to broaden our clinical study reach. We have also expanded our preclinical programs into new therapeutic indications, presenting positive preclinical data supporting our technologies used in these programs at one of the largest and most attended cancer research conferences. In addition, we've strengthened our global intellectual property estate, which builds protection for our lead drug candidate. We look forward to achieving a number of important catalysts in the coming months that will further position Genprex as a leader in gene therapy."
To read the stockholder letter in its entirety, a digital copy of the Company's stockholder letter can be found on the Company's website here.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the appointment and transition of management personnel and other succession plan-related activities; Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-issues-stockholder-letter-and-provides-2024-corporate-update-302184189.html
SOURCE Genprex, Inc.
FAQ
What recent clinical milestones has Genprex (GNPX) achieved in 2024?
How is Genprex (GNPX) broadening its clinical study reach?
What new therapeutic areas is Genprex (GNPX) exploring?
How has Genprex (GNPX) strengthened its intellectual property?
What are the key upcoming catalysts for Genprex (GNPX) in 2024?
